journal article·2022-12-28

Bioinspired Nanocomplexes Comprising Phenolic Acid Derivative and Human Serum Albumin for Cancer Therapy

Zhaomeng Wang, Yanhua Liu, Shuo Li, Fanlin Meng, Jiang Yu, Shuang Zhou, Songtao Dong, Jianying Ye, Lingxiao Li, Chuang Zhang, Shengnan Qiu, Guimei Lin, Hongzhuo Liu, Shyh-Dar Li, Zhonggui He, Yongjun Wang

Nano Letters· Volume 22· Issue 24
Publisher page

Abstract

Inspired by the natural phenomenon of phenolic-protein interactions, we translate this "naturally evolved interaction" to a "phenolic acid derivative based albumin bound" technology, through the synthesis of phenolic acid derivatives comprising a therapeutic cargo linked to a phenolic motif. Phenolic acid derivatives can bind to albumin and form nanocomplexes after microfluidic mixing. This strategy has been successfully applied to different types of anticancer drugs, including taxanes, anthraquinones, etoposides, and terpenoids. Paclitaxel was selected as a model drug for an in-depth study. Three novel paclitaxel-phenolic acid conjugates have been synthesized. Molecular dynamics simulations provide insights into the self-assembled mechanisms of phenolic-protein nanocomplexes. The nanocomplexes show improved pharmacokinetics, elevated tolerability, decreased neurotoxicity, and enhanced anticancer efficacies in multiple murine xenograft models of breast cancer, in comparison with two clinically approved formulations, Taxol (polyoxyethylated castor oil-formulated paclitaxel) and Abraxane (nab-paclitaxel). Such a robust system provides a broadly applicable platform for the development of albumin-based nanomedicines and has great potential for clinical translation.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoparticle-Based Drug Delivery · Protein Interaction Studies and Fluorescence Analysis · Carbon and Quantum Dots Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Wuya College of Innovation, Shenyang Pharmaceutical University, Shenyang, Liaoning 110016, People’s Republic of China

Department of Pharmaceutics, School of Pharmacy, Ningxia Medical University, No. 1160, Shengli Street, Yinchuan 750004, People’s Republic of China

School of Pharmacy, Shandong University, Jinan 250000, People’s Republic of China

Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada

Funding

National Natural Science Foundation of China · Shenyang Science and Technology Bureau

References (35)

Show source-provided references
1. 10.1016/j.biomaterials.2009.10.04410.1016/j.biomaterials.2009.10.044 ↗
2. 10.1016/j.jconrel.2007.02.01010.1016/j.jconrel.2007.02.010 ↗
3. 10.1016/j.addr.2020.07.02410.1016/j.addr.2020.07.024 ↗
4. 10.1080/17425247.2016.119314910.1080/17425247.2016.1193149 ↗
5. 10.1016/j.addr.2018.07.01110.1016/j.addr.2018.07.011 ↗
6. 10.1016/j.addr.2007.08.04410.1016/j.addr.2007.08.044 ↗
7. 10.1038/nature1297810.1038/nature12978 ↗
8. 10.1016/j.jconrel.2018.07.01010.1016/j.jconrel.2018.07.010 ↗
9. 10.1021/acs.jmedchem.8b0029310.1021/acs.jmedchem.8b00293 ↗
10. 10.1021/jacs.9b0427210.1021/jacs.9b04272 ↗
11. 10.1021/ja503826910.1021/ja5038269 ↗
12. 10.1016/j.ijpharm.2007.03.03610.1016/j.ijpharm.2007.03.036 ↗
13. 10.1016/j.jconrel.2008.05.01010.1016/j.jconrel.2008.05.010 ↗
14. 10.1158/1078-0432.CCR-05-163410.1158/1078-0432.CCR-05-1634 ↗
15. 10.1016/j.jconrel.2011.07.03110.1016/j.jconrel.2011.07.031 ↗
16. 10.1007/s12272-020-01204-710.1007/s12272-020-01204-7 ↗
17. 10.1016/j.drudis.2019.09.01710.1016/j.drudis.2019.09.017 ↗
18. 10.1016/j.jconrel.2013.05.04110.1016/j.jconrel.2013.05.041 ↗
19. 10.3390/pharmaceutics1207060410.3390/pharmaceutics12070604 ↗
20. 10.1111/j.1753-4887.1998.tb01670.x10.1111/j.1753-4887.1998.tb01670.x ↗
21. 10.1016/j.addr.2021.11387010.1016/j.addr.2021.113870 ↗
22. 10.1002/anie.20100004410.1002/anie.201000044 ↗
23. 10.1021/acs.accounts.0c0015010.1021/acs.accounts.0c00150 ↗
24. 10.1021/bm034511010.1021/bm0345110 ↗
25. 10.1021/bi970032810.1021/bi9700328 ↗
26. 10.1002/adma.20200735610.1002/adma.202007356 ↗
27. 10.1002/anie.20200208910.1002/anie.202002089 ↗
28. 10.1200/JCO.1995.13.10.264310.1200/JCO.1995.13.10.2643 ↗
29. 10.1358/dot.2010.46.10.151901910.1358/dot.2010.46.10.1519019 ↗
30. 10.1016/S0959-8049(98)00228-710.1016/S0959-8049(98)00228-7 ↗
31. 10.2174/09298670978880331210.2174/092986709788803312 ↗
32. 10.1016/j.tips.2019.03.00210.1016/j.tips.2019.03.002 ↗
33. 10.1021/jf010897z10.1021/jf010897z ↗
34. 10.1016/j.ajps.2018.11.00110.1016/j.ajps.2018.11.001 ↗
35. 10.1016/0022-2836(82)90515-010.1016/0022-2836(82)90515-0 ↗